Iron overload may induce liver toxicity after hematopoietic stem cell transplantation (HSCT), but it is not known if iron depletion prior to HSCT can reduce the risk of severe toxicity in this setting. We used subcutaneous recombinant erythropoietin (EPO) (25 UI/kg) three times a week and phlebotomy once a week, to prevent liver toxicity in a patient with advanced acute leukemia and liver disease due to severe iron overload, previous drug toxicity and hepatitis C viral infection. Over the 9 months prior to allogeneic HSCT, 34 phlebotomies were carried out. Serum ferritin dropped from 2964 to 239 g/l and the ALT dropped to near normal values. At allogeneic HSCT no liver toxicity was observed, suggesting that iron depletion in the pretransplant period may contribute to reducing transplant-related toxicity in selected cases.
The preparative regimens for hematopoietic transplantation (HSCT) may induce acute hepatic dysfunction and severe veno-occlusive disease (VOD), which may result in hepatic encephalopathy, hepato-renal syndrome and multiorgan failure. In the allogeneic setting, previous liver disease is a major risk factor predisposing to hepatic toxicity, 1 and patients with increased ALT at the time of HSCT are considered to have on average a four-fold increased risk of VOD. 2 For this reason, many centers exclude patients with active hepatitis from allogeneic HSCT because of an unacceptable risk of transplant toxicity. 3 Several approaches have been used to control the hypercoagulable state associated with liver damage in an attempt to minimize the risk of VOD, but for patients at high risk this practice may not be useful and alternative treatments to prevent VOD have either proven ineffective or been far less studied. Since most patients with hematological malignancy and liver dysfunction frequently develop iron overload, it is possible that iron deposition is one factor involved in the liver damage after HSCT, and iron depletion prior to HSCT may contribute to reducing risk of VOD. We used this approach in a patient with acute promyelocytic leukemia who also had chronic liver disease due to a combination of severe iron overload, hepatitis C viral (HCV) infection and previous drug toxicity. Prior to allogeneic HSCT, she was treated with recombinant erythropoietin (EPO) and weekly phlebotomies. This treatment markedly reduced iron stores, improved liver function tests, and there was no liver toxicity after transplantation.
Case report
A 26-year-old female was admitted for allogeneic HSCT in December 1997 for advanced acute promyelocytic leukemia (APL). She was diagnosed in February 1993, and entered complete remission after induction therapy with two courses of cytarabine and daunomycin. After consolidation with intermediate-dose cytarabine and mitoxantrone, she received an autologous HSCT conditioned with busulfan and cyclophosphamide in September 1993. Major toxic events following this transplantation were grade III hemorrhagic cystitis and grade II hepatic dysfunction with ascites and peak bilirubin of 3.16 mg/dl (normal Ͻ1.2 mg/dl), AST 630 UI/l (normal Ͻ45 UI/l) and ALT 380 UI/l (normal Ͻ45 UI/l). She received multiple transfusions comprising 84 packed red cells units. By May 1994 she remained in complete remission, but liver tests were still abnormal with AST 414 UI/l, ALT 740 UI/l, alkaline phosphatase 280 UI/l (normal Ͻ150 UI), and serological evidence of HCV infection was detected (ELISA IgG and RNA RT-PCR). Serum ferritin was increased to 940 g/l (normal Ͻ200 g/l). With no further treatment, AST and ALT progressively returned to near normal values. She had a leukemic relapse in March 1995, and was treated with alltrans retinoic acid (ATRA) combined with standard-dose cytarabine and idarubicin. After prolonged myelosuppression that required the transfusion of 18 packed red cell units, she achieved a second remission. A trial of maintenance therapy with mercaptopurine and methotrexate was abandoned due to a 10-to 15-fold increase in ALT levels. After that, severe iron overload with a serum iron of 46 mol/l (normal 6-28) and ferritin of 3770 g/l was detected. In September 1996, the APL relapsed and a third remission was again obtained with ATRA. Liver dysfunction (AST 102 UI/l and ALT 279 UI/l) and iron overload (serum iron 39 mol/l and ferritin 2964 g/l) persisted, and allogeneic HSCT was deferred due to concerns about transplant-related toxicity. She was then treated with monthly courses of either idarubicin (8 
Iron depletion
Regular phlebotomies were poorly tolerated due to anemia. Therefore from February 1997, recombinant erythropoietin (EPO), 2000 UI (25 UI/kg) three times a week, was given subcutaneously to permit an increase in the frequency of phlebotomies (450 ml) to once a week if base line hemoglobin (Hb) exceeded 105 g/l. After 20 phlebotomies, she had a normal erythrocyte MCH (30.2 pg), reticulocyte count (2.6%, 90 × 10 9 /l) and serum iron (9.5 mol/l) indicating adequate mobilization of iron stores and supply of iron for erythropoiesis. Serum ferritin dropped to 860 g/l and liver function tests improved, with AST and ALT levels reduced to 62 UI/l and 98 UI/l, respectively. In October 1997, after 9 months of treatment with EPO, 34 weekly phlebotomies had been undertaken with good tolerance and no adverse effects, and on only two occasions was the Hb below the 105 g/l threshold. In October, the erythrocyte count was 3.29 × 10 12 /l, Hb 102 g/l, MCH 27.9 pg, serum iron 5.5 mol/l, and ferritin 239 g/l. Bone marrow showed 10% atypical promyelocytes. ATRA was again given and no further phlebotomy was performed, but she underwent HSCT 1 month later with persistent leukemia.
Allogeneic HSCT and course
Base line laboratory values at HSCT were close to normal: WBC 2.81 × 10 9 /l, Hb 99 g/l, platelets 129 × 10 9 /l, AST 80 UI/l, ALT 109 UI/l and normal bilirubin and alkaline phosphatase values. Liver biopsy showed a picture of chronic fibrotic hepatopathy similar to previous biopsies, except for a marked reduction in stainable iron. There was intense periportal fibrosis and a moderate lymphocyte infiltrate with focal hepatocyte necrosis and regenerative foci. Minor siderosis was detected in Kupffer cells but not in hepatocytes, which showed cytoplasmic acidophilic bodies, steatosis and hydropic degeneration. The patient was conditioned with melphalan 120 mg/m 2 , two doses on days Ϫ3 and Ϫ2 (total dose 240 mg/m 2 ). She also received ATRA (45 mg/m 2 ) daily until day Ϫ7, etoposide 2 mg/kg in three divided doses on days Ϫ10, Ϫ9 and Ϫ8 (total dose 6 mg/kg), recombinant erythropoietin (25 UI/kg) three times a week until day +8, daily continuous heparin infusions (15 UI/kg) until day +15, and standard GVHD prophylaxis with cyclosporin and short-course methotrexate. Filgrastim mobilized PBSC from her 16-year-old brother were infused (9.76 × 10 6 /kg CD34 + cells and 1.04 × 10 8 /kg CD3 + cells). Regimen-related toxicity was mild, with grade I mucositis and granulocytopenic fever. Of note, liver toxicity was absent during the post-transplant follow-up. Peak bilirubin was 1.6 mg/dl, AST 43 UI/l and ALT 48 UI/l. Granulocyte (Ͼ1.0 × 10 9 /l) and platelet (Ͼ100 × 10 9 /l) engraftment occurred on day +11 and +13, respectively. Grade II GVHD occurred and responded promptly to methylprednisolone therapy. She was discharged on day +31 in good clinical condition, in complete remission of APL and with normal liver function tests. At 4 months, coinciding with withdrawal of immunosuppressive drugs, there was a transient increase in AST (467 UI/l), ALT (415 UI/l), alkaline phosphatase (459 UI/l) and ferritin (1185 g/l), which was attributed to activation of HCV infection. At the last follow-up, 9 months after HSCT she is alive and well, with controlled chronic GVHD and mild liver dysfunction (ALT 112 UI/l).
Discussion
We have demonstrated that significant iron depletion can be achieved in a relatively short period of time with the use of EPO and phlebotomy. This approach may allow us to reduce iron load and minimize organ dysfunction in patients with hematological malignancies in preparation for allogeneic HSCT, when a high risk of transplant-related toxicity is anticipated. In such cases, the usual method of eliminating excess iron by blood drawing with repeated phlebotomies is impractical, as patients usually have anemia or a reduced hematopoietic reserve that preclude phlebotomy or limit volume or frequency, lengthening the time required to achieve significant iron depletion. Recent studies have shown that EPO can be used safely in patients with malignancy to increase red cell mass and avoid transfusions, and in blood donors to increase the potential for donation. Interestingly, the red cell regeneration induced by EPO is far more active in donors with iron overload than in those who have normal iron stores. 4 EPO has also been successfully used to allow an increase in the frequency of phlebotomies in iron loaded anemic patients. 5 We found that EPO administration in this patient with advanced leukemia was safe, well-tolerated and permitted weekly phlebotomies on an outpatient basis. A reduction in iron stores and plasma iron, and improved liver function were achieved promptly, contributing to a favorable outcome after allogeneic HSCT, although other factors such as low-dose heparin infusions and conditioning with high-dose melphalan, a regimen associated with a low toxic profile and full donor engraftment, 6 might have contributed to preventing liver toxicity.
To our knowledge, there are no published studies addressing this issue and it is still not known which patients would benefit from pretransplant iron depletion. Transfusional siderosis is frequent in patients with leukemia, myelodysplasia and other advanced neoplasias referred for allogeneic HSCT. However, in most cases iron overload has no adverse consequences and iron-related organ dysfunction only occurs in severe hemosiderosis. The liver is a preferential target for iron deposition, which initially involves macrophages, and then parenchymal cells at more advanced stages. Typically, iron overload induces chronic fibrotic hepatopathy, and it may also worsen the damage caused by different agents, such as drugs or viruses. The main cause of chronic liver dysfunction in hematological malignancies is HCV infection. HCV is almost always transmitted by transfusion of contaminated blood products, so multitransfused patients are likely to have both HCV infection and iron overload. In the HSCT setting, HCV hepatitis is considered a risk for VOD, 7 but some studies have found that the serological status for HCV does not influence acute liver toxicity after HSCT, 8, 9 suggesting that rather than HCV infection, outcome is affected by the severity of liver damage or other coexisting factors. Patients referred for allogeneic HSCT with liver dysfunction due to HCV and iron overload seem to be definite candidates for pretransplant iron depletion in order to reduce the risk of VOD. There are previous reports of the beneficial effects of phlebotomy in patients with chronic viral hepatitis treated with ␣-interferon. 10 In addition, HCV infection 9, 11 and iron overload, 12 well-known causes of long-term liver dysfunction after HSCT, may be improved by iron depletion alone. [12] [13] [14] The rationale for the beneficial effect of eliminating the excess iron prior to HSCT is that free serum iron, which is increased in iron overloaded patients, can activate the free radicals generated by cytotoxic agents and induce organ damage by lipid peroxidation. 15 Patients with liver disease undergoing HSCT increase their iron load and free serum iron, which reduces serum antioxidant activity; these effects may be involved in liver dysfunction after HSCT. [16] [17] [18] In conclusion, treatment with EPO and phlebotomy prior to allogeneic HSCT in selected patients with liver disease and iron overload may reduce the risk of post-transplant liver dysfunction and improve outcome.
